CN1754570A - Contain slow release microphere for injection of interferon or its analog and preparation method thereof - Google Patents
Contain slow release microphere for injection of interferon or its analog and preparation method thereof Download PDFInfo
- Publication number
- CN1754570A CN1754570A CN 200410012069 CN200410012069A CN1754570A CN 1754570 A CN1754570 A CN 1754570A CN 200410012069 CN200410012069 CN 200410012069 CN 200410012069 A CN200410012069 A CN 200410012069A CN 1754570 A CN1754570 A CN 1754570A
- Authority
- CN
- China
- Prior art keywords
- interferon
- microsphere
- analog
- injection
- slow release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to slow release microphere for injection of interferon or its analog and preparation method thereof.This sustained-release micro-spheres comprises in microsphere weight, and the interferon of 0.1～10% (w/w) or its analog and 50～99.9% (w/w) molecular weight be 5,000～70, the pharmaceutical polymers of the biodegradable and bio-compatible between 000 dalton.It can adopt method preparations such as W/O/W method, S/O/O method, spray drying method.Microball preparation envelop rate of the present invention is greater than 75%, and sustainable release reduced the medication number of times about 15 days, 30 days or 60 days, improved bioavailability, reduced systemic toxic side effect, increased patient compliance.
Description
Technical field
The present invention relates to slow release microphere for injection of interferon or its analog and preparation method thereof.
Background technology
Find by retrieval, the preparation of interferon or its analog or salt has buccal tablet, solution, injection, patch, ointment etc., these dosage forms or since the half-life of interferon or its analog shorter, cause eliminating very fast, or owing to non local use makes medicine on the low side and the whole body toxic and side effects is big at partial dose, clinical practice is very limited.
Summary of the invention
The technical problem to be solved in the present invention, i.e. the object of the invention provides the slow release microphere for injection of a kind of interferon or its analog.
Through research for a long time, the present inventor finds, to account for the interferon of 0.1～10% (w/w) of microsphere weight or its analog and 50～99.9% (w/w) molecular weight 5,000～70, the pharmaceutical polymers of the biodegradable and bio-compatible between 000 dalton is made slow release microphere for injection by appropriate methodology, can realize above-mentioned purpose of the present invention.
Therefore, the invention provides a kind of slow release microphere for injection, it is characterized in that it comprises in the interferon of microsphere weight 0.1～10% (w/w) or its analog and 50～99.9% (w/w) molecular weight 5,000～70, biodegradable between 000 dalton and have the pharmaceutical polymers of biocompatibility, the mean diameter of described microsphere is between 10～100 μ m.
The either party method preparation of slow release microphere for injection of the present invention in can be by the following method.
Multi-emulsion method, it is characterized in that after an amount of interferon or its analog and stabilizing agent dissolving or being suspended in the aqueous solution that contains nonionic emulsifier, join in the organic solution that contains described pharmaceutical polymers, after treatment, join the outer aqueous phase that contains nonionic emulsifier again and form microsphere.
No water law, it is characterized in that the micropowder of an amount of interferon or its analog and stabilizing agent thereof is joined in the organic solvent of pbz polymer material, behind the ultrasonic suspendible of water-bath, join again in a certain amount of Oleum Gossypii semen, make it be solidified into microsphere with the decentralized photo extraction, add light petroleum ether then, make the microsphere completion of cure.
The cold nebulization extraction method is characterized in that an amount of interferon or its analog powder suspension forming droplet by spraying in being dissolved with the organic solvent of macromolecular material, and is freezing in liquid nitrogen, makes with low temperature organic cosolvent extracting dissolve polymer.
The phase coacervation after it is characterized in that an amount of interferon or its analog be scattered in suitable macromolecule material solution, adds flocculating agent in this solution, the macromolecular material dissolubility is reduced and separate out, and forms good microsphere.
Sustained-release micro-spheres of the present invention can also be by after earlier being prepared into liposome with interferon or its analog, and the described pharmaceutical polymers that reuse is fit to is rolled into the method for microsphere and makes.
Sustained-release micro-spheres of the present invention can also be by after earlier being prepared into nanoparticle with interferon or its analog, and the described pharmaceutical polymers that reuse is fit to is rolled into the method for microsphere and makes.
Sustained-release micro-spheres of the present invention can also be by joining interferon or its analog solution in the micropowder silica gel, and after fully being adsorbed by micropowder silica gel, the described pharmaceutical polymers that reuse is fit to is rolled into the method for microsphere and makes.
Interferon of the present invention and analog thereof comprise salt, the PEGization of alpha-interferon, beta-interferon, gamma interferon, various interferon, the various interferon derivatives that methylate and modify with other group.
Pharmaceutical polymers of the present invention is a gelatin, albumin, polylactide-co-glycolide, polylactic acid, polyglycolic acid, poly--the 3-butyric ester, poly-adjacent ester, polyanhydride, poly butyric ester-hydroxyl pentanoate copolymer, the polypropylene glucosan, polylactone, polyvinyl alcohol (PVA), Polyethylene Glycol (PBG), hydroxyacetic acid, polylactic acid-polyglycol, polylactic acid-glycolic guanidine-acetic acid copolymer (PLGA), a kind of in polyglycolic acid-Polyethylene Glycol or two or more mixture wherein.
Preferred polylactic acid, polylactide-co-glycolide, polylactic acid-glycolic guanidine-acetic acid copolymer or poly butyric ester-hydroxyl pentanoate copolymer.
More preferably molecular weight is 5,000～70, polylactic acid-glycolic guanidine-acetic acid copolymer between 000 dalton, wherein the ratio of lactic acid and hydroxyacetic acid is 20: 80～80: 20, perhaps molecular weight is 5, polylactide-co-glycolide between 000～70,000 dalton, wherein the polymerization ratio of lactide and Acetic acid, hydroxy-, bimol. cyclic ester is 20: 80～80: 20.
Also can comprise pharmaceutically acceptable protein stabiliser, surfactant and other additives according to microsphere of the present invention.
Described protein stabiliser is selected from HSA, mannitol, trehalose, EDTA, Zn salt, Mg (OH)
2, CaCO
3, ZnCO
3Deng.
Described surfactant is selected from poloxamer, lecithin, Macrogol 2000 or Polyethylene Glycol 5000 etc.
Described other additives are selected from micropowder silica gel, carry positive ionic material such as aminoacid etc.
The microball preparation envelop rate of interferon of the present invention or its analog is greater than 75%, and sustainable release reduced the medication number of times about 15 days, 30 days or 60 days, improved bioavailability, reduced systemic toxic side effect, increased patient compliance.
Description of drawings
Fig. 1 is the cumulative in vitro release profiles of microsphere among the embodiment 1.
Fig. 2 is the cumulative in vitro release profiles of microsphere among the embodiment 2.
Fig. 3 is the cumulative in vitro release profiles of microsphere among the embodiment 3.
Fig. 4 is the release in vitro curve of 7 days microsphere of embodiment 6 slow release.
Fig. 5 is the release in vitro curve of 7 days microsphere of embodiment 9 slow release.
Fig. 6 is the release in vitro curve of 7 days microsphere of embodiment 10 slow release.
Fig. 7 is the release in vitro curve of 30 days microsphere of embodiment 7 slow release.
Fig. 8 is the release in vitro curve of 30 days microsphere of embodiment 8 slow release.
Fig. 9 be among the embodiment 1 microsphere at the intravital biological activity～time graph of mice.
The specific embodiment
Further specify the preparation method of the slow release microphere for injection of interferon of the present invention or its analog by the following examples.
Embodiment 1: multi-emulsion method prepares the alpha-interferon microsphere
(about 5mg is with Zn with a certain amount of alpha-interferon
2+In conjunction with the back) be dissolved in the 0.5ml 20mg/ml gelatin solution (containing 10% trehalose), after 5000rpm stirs 30s, join among the dichloromethane solution 1.25ml that contains 150mg PLGA, under the rotating speed of 5000rpm, stirred 2 minutes, and joined 20ml then and contain in the aqueous solution of 6%PVA, with 200rpm speed magnetic agitation 5 minutes, and then join in the 500ml aqueous solution that contains 2% PVA, solvent evaporates is carried out in stirring, and washing, centrifugal, lyophilization then collected promptly.The mean diameter of microsphere is that 32 μ m, drug loading are 2.95%, envelop rate is 97.34%.
Embodiment 2: multi-emulsion method prepares the beta-interferon microsphere
(about 5mg is with Zn with a certain amount of alpha-interferon
2+In conjunction with the back) be dissolved in 0.5ml 20mg/ml gelatin solution and (contain 2%CaCO
3Micropowder) in, after 5000rpm stirs 30s, join among the dichloromethane solution 0.25ml that contains 60mg PLGA (molecular weight is 5000), under the rotating speed of 5000rpm, stirred 2 minutes, and joined 10ml then and contain in the aqueous solution of 6%PEG, with 200rpm speed magnetic agitation 5 minutes, and then join in the 200ml aqueous solution that contains 2% PEG, solvent evaporates is carried out in stirring, and washing, centrifugal, lyophilization then collected promptly.
Embodiment 3: multi-emulsion method prepares the gamma interferon microsphere
(about 5mg is with Zn with a certain amount of gamma interferon
2+In conjunction with the back) be dissolved in the 0.5ml 20mg/ml gelatin solution (containing 10%EDTA etc.), after 8000rpm stirs 30s, join among the dichloromethane solution 1.25ml that contains 150mg PLGA (molecular weight is 1000), under the rotating speed of 3000rpm, stirred 2 minutes, joining 20ml then contains in the aqueous solution of 6%PEG, with 200rpm speed magnetic agitation 5 minutes, and then join in the 500ml aqueous solution that contains 2% PEG, solvent evaporates is carried out in stirring, washing, centrifugal, lyophilization then collected promptly.
Embodiment 4: anhydrous legal system is equipped with the alpha-interferon microsphere
The about 150mg of PLGA is dissolved among the acetonitrile 1ml, then to wherein adding the about 10mg of alpha-interferon micropowder micropowder, behind the ultrasonic 30s suspendible of water-bath, join in the Oleum Gossypii semen (containing poloxamer etc.) of 205ml as emulsifying agent, 2000rpm stirring and emulsifying 2 minutes, the acetonitrile solution that constantly extracts in the emulsion droplet with decentralized photo makes it be solidified into microsphere, add light petroleum ether (boiling point 60-90 ℃) then, continue to stir and to make the microsphere completion of cure, centrifugal, petroleum ether, lyophilization are promptly.
Embodiment 5: anhydrous legal system is equipped with ω-interferon microsphere
The about 150mg of PLGA is dissolved among the acetonitrile 1ml, then to the micropowder 5mg that wherein adds ω-interferon, behind the ultrasonic 30s suspendible of water-bath, join in the Oleum Gossypii semen (containing lecithin) of 30ml as emulsifying agent, 2000rpm stirring and emulsifying 2 minutes, the acetonitrile solution that constantly extracts in the emulsion droplet with decentralized photo makes it be solidified into microsphere, add light petroleum ether (boiling point 60-90 ℃) then, continue to stir and to make the microsphere completion of cure, centrifugal, petroleum ether, lyophilization are promptly.
Embodiment 6: the cold nebulization extraction method prepares the alpha-interferon microsphere
The about 5mg of alpha-interferon powder is suspended among the dichloromethane solution 1ml that is dissolved with 100mgPLGA, freezing in liquid nitrogen by spraying to such an extent that method forms droplet, and with the dichloromethane of organic cosolvent ether extracting dissolve polymer promptly.
Embodiment 7: make earlier to be rolled into behind the liposome again and pray for ball
Adopt film dispersion method to prepare the alpha-interferon liposome, the liposome powder that will be equivalent to the 5mg interferon then joins among the dichloromethane solution 1ml of 100mg/ml PLGA, behind ultrasonic 30s suspendible, join among the aqueous solution 15ml of 5%PVA, join in the 1%PVA solution of 200ml after stirring 2min with the rotating speed of about 2000rpm, after continue stirring 4h with the slow-speed of revolution, washing, centrifugal, lyophilization are promptly.
Embodiment 8: be rolled into microsphere again after making nanoparticle earlier
After adopting the natural polymer method to be prepared into the alpha-interferon nano-granule freeze-dried powder, join among the dichloromethane solution 1ml of 50mg/ml PLGA, join among the aqueous solution 15ml of 5%PVA after stirring the 0.5min suspendible, join in the 1%PVA solution of 200ml after stirring 2min with the rotating speed of about 2000rpm, after continue stirring 4h with the slow-speed of revolution, washing, centrifugal, lyophilization are promptly.
Embodiment 9: be rolled into microsphere again after micropowder silica gel absorption
Earlier the alpha-interferon buffer is joined in the micropowder silica gel; after fully being adsorbed by micropowder silica gel; add freeze drying protectants such as mannitol; after lyophilization is prepared into lyophilized powder; get in the dichloromethane solution that the amount that is equivalent to the 5mg interferon approximately joins 100mg/ml PLGA; join behind the ultrasonic suspendible 30s among the 5%PVA aqueous solution 15ml; join in the 1%PVA solution behind the rotating speed stirring and emulsifying 2min with about 2000rpm; continue to stir 4h with the slow-speed of revolution; solvent flashing, after washing, centrifugal, the lyophilization promptly.
Embodiment 10: the phase coacervation prepares microsphere
Alpha-interferon lyophilized powder or the about 5mg of alpha-interferon solution are joined in the PLGA dichloromethane solution of 150mg/ml in right amount, and behind the rotating speed stirring 30s with about 2000rpm, the reduction rotating speed is 1000rpm, and injects silicone oil.After being separated, suspension is changed in the hexane of 500ml, after 20 ℃ of rotating speeds with about 300rpm of constant temperature stir 30min, collect microsphere, the 500ml hexane wash, lyophilization is promptly.
The mensuration of microspherulite diameter
Test specimen: according to the microsphere of the embodiment of the invention 1,2,3,4,5,6,7,8,9,10 methods preparation.
Experimental apparatus: the optical microscope or the laser granulometry of band graduated eyepiece.
Experimental technique:
Light microscope determining: will observe down with last embodiment microsphere at microscope (laser counter) behind the microsphere powder homodisperse, and write down microspherulite diameter, the microsphere sum is no less than 200, and data are carried out statistical disposition, investigates the mean diameter and the particle size distribution situation of microsphere.
Laser granulometry is measured: take by weighing suitable laboratory sample, use laser granulometry to measure.
The mensuration of microsphere drug loading and envelop rate
Test specimen: according to the microsphere of the embodiment of the invention 1,2,3,4,5,6,7,8,9,10 methods preparation.
Experiment reagent: BCA determining the protein quantity test kit, NaOH, SDS
Experimental apparatus: ultraviolet spectrophotometer, vortex instrument, centrifuge
Experimental technique: precision takes by weighing the about 10mg of laboratory sample, adds in the mixed solution of 5.0ml 0.1MNaOH/0.5SDS (w/v), and 37 ℃ of water-baths vibration 24h dissolve microsphere fully, adds the about 280 μ l of 2M HCL and transfers pH about 7.0, carries out BCA method determining the protein quantity.
Microsphere prominent released the mensuration with release profiles
Laboratory sample: according to the microsphere of the embodiment of the invention 1,4,6 described method preparations.
Experiment reagent: pH is 7.4 phosphate buffer (contain 0.02% Hydrazoic acid,sodium salt as pressing down the mattress agent, the 0.02%F-68 wetting agent is as release medium)
Experimental apparatus: constant temperature shaker, centrifuge, HPLC instrument.
Experiment condition: temperature: 37 ℃, rotating speed: rpm.
Experimental technique: precision takes by weighing pastille microsphere 10～30mg and puts in the 10ml centrifuge tube, add 1.5ml 10mM pH7.4 buffer, place the water bath with thermostatic control shaking table, under 100rpm hunting speed, 37 ℃ ± 0.5 ℃ temperature conditions, carry out the release in vitro degree of microsphere and measure.
Sampling method: take out centrifuge tube at 2h, 1d, 2d respectively, in the centrifugal 10min of 2000rpm,, took a sample once with above operational approach every 3～4 days later on, and measure the content of IFN with the BCA method with the release medium that whole release medium are taken out and more renewed.
Microsphere is measured at the intravital sustained release property of mice
Laboratory sample: according to the microsphere of the embodiment of the invention 1,2,3 described method preparations.
Laboratory animal: Kunming mouse
Experimental technique: get healthy Kunming mouse, after the random packet, vein gives the microspheres solution of rIFN α, and dosage is 1.5 * 10
4KU rIFN α/kg, 0,1,2,5,8,10,12,15 day eye socket is got blood after administration, and blood sample is got supernatant and is measured wherein IFN-α biological activity behind the centrifugal 15min of 3000rpm.
The bioactive assay method of IFN-α
Laboratory sample: plasma sample.
Experimental apparatus: freezer dryer, centrifuge.
Experimental technique: WISH cell through 0.25% trypsinization, is made into 2.5 * 10 with complete culture solution
5～3.5 * 10
5Individual cell/ml is inoculated in 96 porocyte culture plates, every hole 100 μ l.37 ℃, 5%CO
2Cultivate 4～6 under the condition, the time, supernatant discarded, IFN-α sample solution and standard solution are carried out adding 1～12 hole (sample solution that concentration is high dilutes in advance) from high to low by concentration behind the doubling dilution, set up the contrast of cell contrast and virus control and sample blank simultaneously.Similarity condition was cultivated 18-24 hour, and supernatant discarded adds VSV counteracting toxic substances culture fluid (dosage 100TCID50) 100 μ l, counteracting toxic substances 24 hours, and microscopy cell 50% pathological changes point under the inverted microscope calculates IFN-α and tires.
Claims (10)
1. slow release microphere for injection, it is characterized in that it comprises in the interferon of microsphere weight 0.1～10% (w/w) or its analog and 50～99.9% (w/w) molecular weight 5,000～70, biodegradable between 000 dalton and have the pharmaceutical polymers of biocompatibility, the mean diameter of described microsphere is between 10～100 μ m.
2. according to the slow release microphere for injection of claim 1, wherein said pharmaceutical polymers is selected from a kind of in gelatin, albumin, polylactide-co-glycolide, polylactic acid, polyglycolic acid, poly--the 3-butyric ester, poly-adjacent ester, polyanhydride, poly butyric ester-hydroxyl pentanoate copolymer, polypropylene glucosan, polylactone, polyvinyl alcohol, Polyethylene Glycol, hydroxyacetic acid, polylactic acid-polyglycol, polylactic acid-glycolic guanidine-acetic acid copolymer, the polyglycolic acid-Polyethylene Glycol or two or more mixture wherein.
3. according to the slow release microphere for injection of claim 2, wherein said pharmaceutical polymers is a polylactic acid-glycolic guanidine-acetic acid copolymer, and wherein molecular weight is 5,000～70, and between 000 dalton, the ratio of lactic acid and hydroxyacetic acid is 20: 80～80: 20; Or polylactide-co-glycolide, wherein molecular weight is 5,000～70, and between 000 dalton, the ratio of lactide and Acetic acid, hydroxy-, bimol. cyclic ester is 20: 80～80: 20.
4. method for preparing the slow release microphere for injection of claim 1, it is characterized in that after an amount of interferon or its analog and stabilizing agent dissolving or being suspended in the aqueous solution that contains nonionic emulsifier, join in the organic solution that contains described pharmaceutical polymers, after treatment, join the outer aqueous phase that contains nonionic emulsifier again and form microsphere.
5. method for preparing the slow release microphere for injection of claim 1, it is characterized in that the micropowder of an amount of interferon or its analog and stabilizing agent thereof is joined in the organic solvent of pbz polymer material, behind the ultrasonic suspendible of water-bath, join again in a certain amount of Oleum Gossypii semen, make it be solidified into microsphere with the decentralized photo extraction, add light petroleum ether then, make the microsphere completion of cure.
6. method for preparing the slow release microphere for injection of claim 1, it is characterized in that an amount of interferon or its analog powder suspension in being dissolved with the organic solvent of macromolecular material, form droplet by spraying, freezing in liquid nitrogen, make with low temperature organic cosolvent extracting dissolve polymer.
7. method for preparing the slow release microphere for injection of claim 1, after it is characterized in that earlier interferon or its analog be prepared into liposome, the described pharmaceutical polymers that reuse is fit to is rolled into microsphere.
8. method for preparing the slow release microphere for injection of claim 1, after it is characterized in that earlier interferon or its analog be prepared into nanoparticle, the described pharmaceutical polymers that reuse is fit to is rolled into microsphere.
9. a method for preparing the slow release microphere for injection of claim 1 is characterized in that interferon or its analog solution are joined in the micropowder silica gel, and after fully being adsorbed by micropowder silica gel, the described pharmaceutical polymers that reuse is fit to is rolled into microsphere.
10. method for preparing the slow release microphere for injection of claim 1, after it is characterized in that an amount of interferon or its analog be scattered in suitable macromolecule material solution, in this solution, add flocculating agent, the macromolecular material dissolubility is reduced and separate out, form good microsphere.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100120692A CN100475264C (en) | 2004-09-28 | 2004-09-28 | Slow release microphere for injection containing interferon or its analog, and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100120692A CN100475264C (en) | 2004-09-28 | 2004-09-28 | Slow release microphere for injection containing interferon or its analog, and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1754570A true CN1754570A (en) | 2006-04-05 |
| CN100475264C CN100475264C (en) | 2009-04-08 |
Family
ID=36688301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100120692A Expired - Fee Related CN100475264C (en) | 2004-09-28 | 2004-09-28 | Slow release microphere for injection containing interferon or its analog, and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100475264C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101618208B (en) * | 2008-06-30 | 2012-07-04 | 江苏先声药物研究有限公司 | Method for preparing sustained-release microspheres containing micronized recombinant human vascular endothelial inhibin |
| CN107176610A (en) * | 2017-05-05 | 2017-09-19 | 浙江理工大学 | A kind of silicon dioxide hollow microsphere and preparation method thereof |
| CN107174731A (en) * | 2017-05-12 | 2017-09-19 | 朱侃 | Medicament nano porous sustained-release device |
| WO2017186073A1 (en) * | 2016-04-26 | 2017-11-02 | 广州帝奇医药技术有限公司 | Preparation method of sustained release microparticulates, sustained release microparticulates thereby and use thereof |
| WO2017186074A1 (en) * | 2016-04-26 | 2017-11-02 | 广州帝奇医药技术有限公司 | Method for preparing sustained release microparticles, prepared sustained release microparticles and application thereof |
| US11730793B2 (en) | 2019-11-25 | 2023-08-22 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5711968A (en) * | 1994-07-25 | 1998-01-27 | Alkermes Controlled Therapeutics, Inc. | Composition and method for the controlled release of metal cation-stabilized interferon |
| DE19746173A1 (en) * | 1997-10-18 | 1999-04-22 | Boehringer Ingelheim Int | Tumor vaccine based on tumor antigens comprises a slow-release system of gamma-interferon (IFN-gamma |
-
2004
- 2004-09-28 CN CNB2004100120692A patent/CN100475264C/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101618208B (en) * | 2008-06-30 | 2012-07-04 | 江苏先声药物研究有限公司 | Method for preparing sustained-release microspheres containing micronized recombinant human vascular endothelial inhibin |
| WO2017186073A1 (en) * | 2016-04-26 | 2017-11-02 | 广州帝奇医药技术有限公司 | Preparation method of sustained release microparticulates, sustained release microparticulates thereby and use thereof |
| WO2017186074A1 (en) * | 2016-04-26 | 2017-11-02 | 广州帝奇医药技术有限公司 | Method for preparing sustained release microparticles, prepared sustained release microparticles and application thereof |
| CN107176610A (en) * | 2017-05-05 | 2017-09-19 | 浙江理工大学 | A kind of silicon dioxide hollow microsphere and preparation method thereof |
| CN107176610B (en) * | 2017-05-05 | 2019-03-01 | 浙江理工大学 | A kind of silicon dioxide hollow microsphere and preparation method thereof |
| CN107174731A (en) * | 2017-05-12 | 2017-09-19 | 朱侃 | Medicament nano porous sustained-release device |
| US11730793B2 (en) | 2019-11-25 | 2023-08-22 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100475264C (en) | 2009-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2865375T3 (en) | Methods and compositions related to synthetic nanocarriers with rapamycin in a stable supersaturated state | |
| FI104954B (en) | Controlled drug delivery system comprising protein or polypeptide interaction and biodegradable polymers | |
| Ribeiro-Costa et al. | In vitro and in vivo properties of usnic acid encapsulated into PLGA-microspheres | |
| RU2464972C2 (en) | Composition with delayed release, including octreotide and two or more polylactide and glycolide copolymers | |
| Lee et al. | Long acting injectable formulations: the state of the arts and challenges of poly (lactic-co-glycolic acid) microsphere, hydrogel, organogel and liquid crystal | |
| JP5675803B2 (en) | Microsphere drug carrier, preparation method, composition and use thereof | |
| AU2004277419B2 (en) | Nanoparticulate therapeutic biologically active agents | |
| ES2607497T3 (en) | Composition of risperidone from controlled release microspheres | |
| JP6067803B2 (en) | Rotigotine, a derivative thereof, or a composition of a pharmaceutically acceptable salt of rotigotine or a derivative thereof | |
| CN1625391A (en) | Cyclosporin-containing sustained release pharmaceutical composition | |
| Yapar et al. | Injectable in situ forming microparticles: a novel drug delivery system | |
| JP2011063596A (en) | Biodegradable composition for controlled release of encapsulated substance | |
| CN1440277A (en) | Particular carrier with active components with improved oral absorbing performance | |
| PT3010962T (en) | Preparation of polylactide-polyglycolide microparticles having a sigmoidal release profile | |
| DK1532985T3 (en) | PROCEDURE FOR PREPARING A COMPOSITION WITH LONG-TERM RELEASE | |
| Martín-Sabroso et al. | Critical attributes of formulation and of elaboration process of PLGA-protein microparticles | |
| JP2015107985A (en) | Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers | |
| CN1438881A (en) | The Controlled release preparation of insulin and its method | |
| CN1676121A (en) | Slow-release micro-ball formulation for tissue, organ local therapy, and its preparing method and use | |
| CN1965810A (en) | Sustained release microsphere formulation of thymosin alpha-1, preparation process and use thereof | |
| CN1754570A (en) | Contain slow release microphere for injection of interferon or its analog and preparation method thereof | |
| CN1304055C (en) | Method for preparing embedded hydrophilic medicinal polymer minisphere or minisac carrier | |
| CN103893129B (en) | Paliperidone sustained-release micro-spheres and injection thereof and the preparation method of this sustained-release micro-spheres | |
| CN1876173A (en) | Thymus pentapeptide slow-release microshpere formulation for injection and its preparation method | |
| CN1754572A (en) | Contain slow release microphere for injection of Alfacon-1 b and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090408 Termination date: 20200928 |